慢性肾脏病伴糖尿病或充血性心力衰竭患者的贫血治疗。

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.

机构信息

Winthrop-University Hospital, Mineola, New York, USA.

出版信息

Kidney Int. 2010 Feb;77(3):175-7. doi: 10.1038/ki.2009.455.

DOI:10.1038/ki.2009.455

PMID:20075952

Abstract

Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.

摘要

贫血在慢性肾脏病（CKD）中很常见。CHOIR 研究发现，与将贫血治疗至 11.3g/dl 的目标血红蛋白水平相比，用促红细胞生成素-α将贫血治疗至 13.5g/dl 会增加复合心血管结局的风险。尚不清楚这种增加是否同样适用于所有患者亚组。我们讨论了 Szczech 及其同事对糖尿病或充血性心力衰竭的 CKD 患者中较高血红蛋白目标的影响的分析。